Beringea has backed Disposable Cubicle Curtains Limited or DCCL with a £3 million investment, a statement about the funding said.
Beringea is a growth capital firm that runs the Proven Venture Capital Trusts while DCCL is a disposable curtains and blinds maker that trades under the name All in One Medical. DCCL's products are patented and actively eliminate toxic and dangerous pathogens. Its curtains and blinds are made and shipped from its Wolverhampton, UK manufacturing facility, the statement said.
DCCL used a portion of the proceeds of Beringea's funding to buy Fantex UK Limited. An anti-microbial biocide maker, Fantex is coming up with biodegradable biocides that can kill pathogens very quickly to be used in sectors outside healthcare. Fantex is currently negotiating with high street retailers for the product, the statement said.
In the statement, Beringea Partner Stephane Mery said, "I am thrilled with our investment, and to be supporting such a great team. I am also delighted that our investment is helping a British company bring its manufacturing back to the UK. DCCL's highly specialised plant in Wolverhampton allows the Company to successfully outperform Chinese manufacturers on both quality and price." Mery led the current deal.
Patients, caregivers and their visitors in hospitals can be infected with hospital acquired infections which have become a worldwide public health concern. A regular fabric cubicle curtain covering a hospital bed has a greater likelihood of developing pathogens on its surface. Because of these deadly bacteria, fabric curtains used in some A&E wards must be changed and cleaned to as many as 20 times in a year. By replacing these linen curtains with anti-microbial and disposable ones, hospitals can avoid an infectious disease outbreak, the statement said.
All in One Chairman and CEO John Hawkins said in the statement, "The disposable curtain market is rapidly growing here in the UK and abroad, and with the investment by Beringea, we are in a position to achieve global market leadership. The acquisition of Fantex allows us to provide a broad spectrum of highly effective pathogen and bacteria eliminating products, applicable across a wide variety of applications, for example keeping fabrics fresh, clean and odourless."
Join the Conversation